SCHEMBL3672019

SCHEMBL3672019

CC1=CC(C)=C(CC(=NNc2c(C)cc(C)cc2C)c2ccccc2)C1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.36
SMN1; SMN2 Q16637 6/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 2/20 0.36
KMT2A Q03164 6/20 0.36
MEN1 O00255 5/20 0.36
ALDH1A1 P00352 7/20 0.35
KDM4E B2RXH2 4/20 0.35
TDP1 Q9NUW8 4/20 0.35
GAA P10253 4/20 0.35
LMNA P02545 2/20 0.35
HPGD P15428 2/20 0.35
HTT P42858 2/20 0.35
THRB P10828 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
NPSR1 Q6W5P4 3/20 0.33
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
CTSL P07711 1/20 0.32
CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3199426 0.86 ALDH1A1 (0.48) MAPTSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3199307 0.84 MAPT (0.36) MAPTSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3212254 0.82 KMT2A (0.39) MAPTSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL3204153 0.81 MAPT (0.38) MAPTSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3199430 0.81 ALDH1A1 (0.40) MAPTSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3204802 0.80 GAA (0.34) MAPTSMN1; SMN2NPC1KMT2AMEN1
SCHEMBL3212263 0.77 MAPT (0.37) MAPTSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3200731 0.76 RAB9A (0.37) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL3202326 0.74 MAPT (0.37) MAPTSMN1; SMN2RAB9ANPC1KMT2A
SCHEMBL3211758 0.72 KMT2A (0.36) MAPTSMN1; SMN2RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732643-B2 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-08 US disclosed
US-20100048933-A1 TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME HANAOKA HIDENORI 2010-02-25 US disclosed
EP-1426379-B1 TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME SUMITOMO CHEMICAL CO (JP) 2009-11-11 EP disclosed
US-20090054607-A1 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same HANAOKA HIDENORI 2009-02-26 US disclosed
US-7439379-B2 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL CO., LTD. (JP) 2008-10-21 US disclosed
US-20040242410-A1 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-12-02 US disclosed
EP-1426379-A1 TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME Sumitomo Chemical Company, Limited (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054607-A1 Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same C1R, C1S, AP1M1 MAPT 2641/4885SMN1; SMN2 3599/4885RAB9A 1759/4885
US-20100048933-A1 TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME C1R, C1S, AP1M1 MAPT 2641/4885SMN1; SMN2 3599/4885RAB9A 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.